ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Phase 3 Auriga Study Among Clinically Relevant Subgroups

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Phase 3 Auriga Study Among Clinically Relevant Subgroups

ASH HIGHLIGHTS 2024 ROUNDTABLE DISCUSSIONS
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speaker

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

Phase 3 Auriga Study Among Clinically Relevant Subgroups

Studies/trials discussed:

Phase 3 Auriga Study Among Clinically Relevant Subgroups
Tagged